137863-60-6

Basic information

• Product Name: Valsartan
• Synonyms: L-VALINE,N-(1-OXOPENTYL)-N-[[2''-(1H-TETRAZOL-5-YL)[1,1''-BIPHENYL]-3-YL]METHYL]-;N-(1-Oxopentyl)-N-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-3-yl]methyl]-L-valine
• CAS NO: 137863-60-6
• Molecular Formula: C₂₄H₂₉N₅O₃
• Molecular Weight: 435.52
• Product Categories: Hypertension
• Mol File: 137863-60-6.mol
• Article Data: 1

Chemical Properties

• Boiling Point: 684.932 °C at 760 mmHg
• Flash Point: 368.034 °C
• Appearance: /
• Density: 1.212
• Vapor Pressure: 1.06E-19mmHg at 25°C
• Refractive Index: 1.586
• PKA: 3.56±0.10(Predicted)
• CAS DataBase Reference: Valsartan(CAS DataBase Reference)
• NIST Chemistry Reference: Valsartan(137863-60-6)
• EPA Substance Registry System: Valsartan(137863-60-6)

Safety Data

• Hazardous Substances Data: 137863-60-6(Hazardous Substances Data)

Usage

General Description

Valsartan is a prescription medication and belongs to a class of drugs known as angiotensin II receptor blockers (ARBs). It works by blocking the action of certain natural substances that tighten the blood vessels, allowing the blood to flow more smoothly and the heart to pump more efficiently. Valsartan is commonly used to treat high blood pressure, heart failure, and to improve the chances of living longer after a heart attack. It is also used to prevent certain types of stroke in people with heart disease. Valsartan is typically taken by mouth and comes in tablet form, and it may be taken with or without food. It is important to follow the doctor's instructions and to take the medication regularly to get the most benefit from it. As with any medication, there may be potential side effects, so patients should talk to their doctor about any concerns or questions they may have.

InChI:InChI=1/C24H29N5O3/c1-4-5-10-21(30)29(22(16(2)3)24(31)32)15-17-11-13-18(14-12-17)19-8-6-7-9-20(19)23-25-27-28-26-23/h6-9,11-14,16,22H,4-5,10,15H2,1-3H3,(H,31,32)(H,25,26,27,28)/t22-/m1/s1

Relevant articles and documents

ACYL COMPOUNDS

Compounds of the formula STR1 in which R 1 is an aliphatic hydrocarbon radical which is unsubstituted or substituted by halogen or hydroxyl, or a cycloaliphatic or araliphatic hydrocarbon radical; X 1 is CO, SO 2, or--O--C(=O)--with the carbon atom of the carbonyl group being attached to the nitrogen atom shown in formula I; X 2 is a divalent aliphatic hydrocarbon radical which is unsubstituted or substituted by hydroxyl, carboxyl, amino, guanidino or a cycloaliphatic or aromatic radical, or is a divalent cycloaliphatic hydrocarbon radical, it being possible for a carbon atom of the aliphatic hydrocarbon radical to be additionally bridged by a divalent aliphatic hydrocarbon radical; R. sub.2 is carboxyl which, if desired, is esterified or amidated, substituted or unsubstituted amino, formyl which, if desired, is acetalized, 1H-tetrazol-5-yl, pyridyl, hydroxyl which, if desired, is etherified, S(O) m--R where m is 0, 1 or 2 and R is hydrogen or an aliphatic hydrocarbon radical, alkanoyl, unsubstituted or N-substituted sulfamoyl or PO n H 2 where n is 2 or 3; X 3 is a divalent aliphatic hydrocarbon; R 3 is carboxyl, 5-tetrazolyl, SO. sub.3 H, PO. sub.2 H 2, PO 3 H 2 or haloalkylsulfamoyl; and the rings A and B independently of one another are substituted or unsubstituted; in free form or in salt form, can be prepared in a manner known per se and can be used, for example, as medicament active ingredients.